Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Simeprevir, Odalasvir, and AL-335 FDC and Interaction with PPIs
NCT03059303Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2017
- Primary completion
- Apr 2017
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of simeprevir, odalasvir and adafosbuvir in hepatitis C (HCV) (13 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration of Simeprevir at 72 hours, Area Under the Plasma Concentration-Time Curve of Simeprevir at 72 hours and 6 more. Started Feb 2017; status: terminated.
02
Drugs
simeprevirodalasviradafosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03059303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03059303.